GSK484 GSK

Product vision
  • Uncomplicated malaria treatment and resistance management
MoA
  • Novel and unknown
Key features
  • Fast killing in vitro and in vivo
  • No resistant mutants identified
  • Low predicted dose (100 mg) and 200 h predicted half-life
Challenges
  • Human PK prediction for low clearance compounds
  • Synthetic route: Palladium used in two chemical steps
Status
  • Metabolite identification ongoing to confirm human PK prediction
  • Photosafety study ongoing
Next milestone
  • Completion of Good Laboratory Practice (GLP) toxicology programme
Previously
  • Also known as MMV1793192
MMV Project Director
  • Dr Cristina Donini